Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michel Farnier

Showing results (1-10 of 144) with videos related to

Pageof 15
Sort By:
Presse Medicale (Paris, France : 1983)|April 21, 2009
[How to manage lipid profiles and their interpretation in patients with coronary heart disease?]Michel Farnier
Atherosclerosis. Supplements|February 10, 2015
Ezetimibe/statin combination therapy to treat patients with type 2 diabetesMichel Farnier
Archives of Cardiovascular Diseases|December 31, 2013
PCSK9: From discovery to therapeutic applicationsMichel Farnier
Current Opinion in Lipidology|May 9, 2013
PCSK9 inhibitorsMichel Farnier
Expert Review of Cardiovascular Therapy|November 25, 2017
Alirocumab for the treatment of hyperlipidemia in high-risk patients: an updated reviewMichel Farnier
Current Opinion in Lipidology|November 3, 2016
Proprotein convertase subtilisin kexin type 9 inhibitors: update from clinical trials to real-world experienceMichel Farnier
Therapie|June 26, 2003
[New antilipemics: prospects]Michel Farnier
Annals of Translational Medicine|April 4, 2018
Lowering low-density lipoprotein cholesterol by PCSK9 inhibition in patients with diabetes on insulin therapy: is it efficacious and safe?Michel Farnier
La Revue Du Praticien|December 6, 2011
[What about HDL cholesterol?]Michel Farnier
Current Cardiology Reports|May 25, 2016
Future Lipid-Altering Therapeutic Options Targeting Residual Cardiovascular RiskMichel Farnier
Pageof 15

Showing results (1-10 of 144) with videos related to

Sort By:
Pageof 15
Presse Medicale (Paris, France : 1983)|April 21, 2009
[How to manage lipid profiles and their interpretation in patients with coronary heart disease?]Michel Farnier
Atherosclerosis. Supplements|February 10, 2015
Ezetimibe/statin combination therapy to treat patients with type 2 diabetesMichel Farnier
Archives of Cardiovascular Diseases|December 31, 2013
PCSK9: From discovery to therapeutic applicationsMichel Farnier
Current Opinion in Lipidology|May 9, 2013
PCSK9 inhibitorsMichel Farnier
Expert Review of Cardiovascular Therapy|November 25, 2017
Alirocumab for the treatment of hyperlipidemia in high-risk patients: an updated reviewMichel Farnier
Current Opinion in Lipidology|November 3, 2016
Proprotein convertase subtilisin kexin type 9 inhibitors: update from clinical trials to real-world experienceMichel Farnier
Therapie|June 26, 2003
[New antilipemics: prospects]Michel Farnier
Annals of Translational Medicine|April 4, 2018
Lowering low-density lipoprotein cholesterol by PCSK9 inhibition in patients with diabetes on insulin therapy: is it efficacious and safe?Michel Farnier
La Revue Du Praticien|December 6, 2011
[What about HDL cholesterol?]Michel Farnier
Current Cardiology Reports|May 25, 2016
Future Lipid-Altering Therapeutic Options Targeting Residual Cardiovascular RiskMichel Farnier
Pageof 15